2.21
price up icon4.25%   0.09
after-market Handel nachbörslich: 2.14 -0.07 -3.17%
loading

Minerva Neurosciences Inc Aktie (NERV) Neueste Nachrichten

pulisher
01:12 AM

Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World

01:12 AM
pulisher
Nov 15, 2024

500: Something went wrong - Investing.com

Nov 15, 2024
pulisher
Nov 15, 2024

Minerva Neurosciences stock hits 52-week low at $2.25 By Investing.com - Investing.com Canada

Nov 15, 2024
pulisher
Nov 10, 2024

Minerva Neurosciences’ (NERV) “Neutral” Rating Reiterated at HC Wainwright - Defense World

Nov 10, 2024
pulisher
Nov 05, 2024

Minerva Neurosciences Reports Positive Earnings Amid FDA Challenges - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Minerva Neurosciences: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 05, 2024
pulisher
Nov 05, 2024

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 05, 2024
pulisher
Oct 29, 2024

Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail

Oct 29, 2024
pulisher
Oct 13, 2024

Cognitive Impairment Disorders Treatment A Game Changer for Global Finance Forecast-Eli Lilly and Company, AstraZeneca, – IndiaPolitics.com - IndiaPolitics.com

Oct 13, 2024
pulisher
Oct 11, 2024

Japan Receptor Tyrosine Protein Kinase ERBB 4 Industry Size, Share, Price, Trends, Forecast (2024-2034) - IndiaPolitics.com

Oct 11, 2024
pulisher
Oct 09, 2024

Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Below 200-Day Moving Average – What’s Next? - Defense World

Oct 09, 2024
pulisher
Sep 30, 2024

Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart

Sep 30, 2024
pulisher
Sep 25, 2024

Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online

Sep 25, 2024
pulisher
Sep 18, 2024

Inari Medical director sells $1.83M in common stock - TipRanks

Sep 18, 2024
pulisher
Sep 18, 2024

Intuitive Machines Shares Soar on NASA Pact for Near-Space Grid - Bloomberg

Sep 18, 2024
pulisher
Sep 18, 2024

Intuitive Machines Stock Soars on New NASA Contract. This Is Big. - Barron's

Sep 18, 2024
pulisher
Sep 18, 2024

Intuitive Machines Stock Is Soaring Wednesday: What's Going On? - Benzinga

Sep 18, 2024
pulisher
Sep 18, 2024

Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga

Sep 18, 2024
pulisher
Sep 17, 2024

After-hours movers: Intuitive Machines, Casella Waste Systems, Galmed Pharma, Edgewise Therapeutics - Investing.com Australia

Sep 17, 2024
pulisher
Sep 16, 2024

Minerva Neurosciences (NASDAQ:NERV) Receives New Coverage from Analysts at StockNews.com - Defense World

Sep 16, 2024
pulisher
Sep 15, 2024

Rathbones Group PLC Increases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat

Sep 15, 2024
pulisher
Sep 13, 2024

INmune Bio stock dips on $13M securities offering - MSN

Sep 13, 2024
pulisher
Aug 23, 2024

Minerva Neurosciences (NASDAQ:NERV) versus AC Immune (NASDAQ:ACIU) Head-To-Head Survey - Defense World

Aug 23, 2024
pulisher
Aug 22, 2024

StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World

Aug 22, 2024
pulisher
Aug 15, 2024

Rubertis Francesco De Net Worth (2024) - GuruFocus.com

Aug 15, 2024
pulisher
Aug 14, 2024

Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Defense World

Aug 14, 2024
pulisher
Aug 09, 2024

Research Analysts Issue Forecasts for Minerva Neurosciences, Inc.’s Q3 2024 Earnings (NASDAQ:NERV) - Defense World

Aug 09, 2024
pulisher
Aug 09, 2024

Minerva Neurosciences (NASDAQ:NERV) Price Target Cut to $5.00 - Defense World

Aug 09, 2024
pulisher
Aug 08, 2024

HC Wainwright Weighs in on Minerva Neurosciences, Inc.’s Q4 2024 Earnings (NASDAQ:NERV) - Defense World

Aug 08, 2024
pulisher
Aug 07, 2024

Minerva Neurosciences: Q2 Earnings Snapshot - San Antonio Express-News

Aug 07, 2024
pulisher
Aug 06, 2024

Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates - GlobeNewswire

Aug 06, 2024
pulisher
Aug 06, 2024

Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com - Defense World

Aug 06, 2024
pulisher
Jul 29, 2024

Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World

Jul 29, 2024
pulisher
Jul 21, 2024

Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World

Jul 21, 2024
pulisher
Jul 13, 2024

Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average of $4.42 - Defense World

Jul 13, 2024
pulisher
Jul 13, 2024

StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World

Jul 13, 2024
pulisher
Jul 12, 2024

Cognitive Behavioral Therapy for Insomnia Market Insights, Industry Outlook, Growing Trends with Top Key Players – MINERVA NEUROSCIENCES INC, CURRAX PHARMACEUTICALS LLC, Pfizer Inc., Sanofi, zydus cadila – TIMC - TIMC

Jul 12, 2024
pulisher
Jul 05, 2024

Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Below 200-Day Moving Average of $4.54 - Defense World

Jul 05, 2024
pulisher
Jul 03, 2024

Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research

Jul 03, 2024
pulisher
Jul 03, 2024

Are Options Traders Betting on a Big Move in Minerva Neurosciences (NERV) Stock? - Yahoo Lifestyle UK

Jul 03, 2024
pulisher
Jul 01, 2024

Design, Sarepta, Wave rise amid overall neurological index decline - BioWorld Online

Jul 01, 2024
pulisher
Jun 30, 2024

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates - Quantisnow

Jun 30, 2024
pulisher
Jun 30, 2024

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market - Quantisnow

Jun 30, 2024
pulisher
Jun 30, 2024

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates - Quantisnow

Jun 30, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023 - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021 - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8 - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021 - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of ... - Quantisnow

Jun 29, 2024
pulisher
Jun 29, 2024

Minerva Neurosciences Announces Promotion of Geoff Race to President - Quantisnow

Jun 29, 2024
pulisher
Jun 27, 2024

Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options - Yahoo New Zealand News

Jun 27, 2024
pulisher
Jun 27, 2024

Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Above 50-Day Moving Average of $2.74 - Defense World

Jun 27, 2024
pulisher
Jun 27, 2024

Minerva Neurosciences (NASDAQ:NERV) Research Coverage Started at StockNews.com - Defense World

Jun 27, 2024
pulisher
Jun 26, 2024

Roche's Ocrevus Subcutaneous Gets European Commission Nod - Markets Insider

Jun 26, 2024
pulisher
Jun 25, 2024

Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod - Zacks Investment Research

Jun 25, 2024
pulisher
Jun 25, 2024

Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod - Yahoo Finance

Jun 25, 2024
pulisher
Jun 21, 2024

Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock? - Yahoo New Zealand News

Jun 21, 2024
pulisher
Jun 19, 2024

Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Above Fifty Day Moving Average of $2.65 - Defense World

Jun 19, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
Kapitalisierung:     |  Volumen (24h):